Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Vehling-Kaiser, U."" wg kryterium: Autor


Wyświetlanie 1-11 z 11
Tytuł :
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Autorzy :
Holch JW; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address: .
Ricard I; Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany.
Stintzing S; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Fischer von Weikersthal L; Praxis für Onkologie/Haematologie, Gesundheitszentrum St. Marien GmbH, Mariahilfbergweg 7, 92224 Amberg, Germany.
Decker T; Onkologie Ravensburg, Elisabethenstrasse 19, 88212 Ravensburg, Germany.
Kiani A; Department of Medicine IV, Klinikum Bayreuth GmbH, Preuschwitzer Strasse 101, 95445 Bayreuth, Germany.
Vehling-Kaiser U; Hämato-onkologische Tagesklinik, Dr. Med. Ursula Vehling-Kaiser, Ländgasse 132-135, 84028 Landshut, Germany.
Heintges T; Department of Medicine II, Lukaskrankenhaus, Preußenstrasse 84, 41462 Neuss, Germany.
Kahl C; Department of Hematology, Oncology and Palliative Care, Klinikum Magdeburg gGmbH, Birkenallee 34, 39130 Magdeburg, Germany.
Kullmann F; Department of Internal Medicine I, Klinikum Weiden, Söllnerstrasse 16, 92637 Weiden, Germany.
Scheithauer W; Department of Internal Medicine I & CCC, Medical University Vienna, Spitalgasse 23, 1090 Vienna, Austria.
Moehler M; University Medical Center Mainz, I. Dept. of Internal Medicine, Langenbeckstrasse 1, 55131 Mainz, Germany.
Jelas I; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Modest DP; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Westphalen CB; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
von Einem JC; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Michl M; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Heinemann V; Department of Internal Medicine III, Comprehensive Cancer Center Munich, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Jan; Vol. 106, pp. 115-125. Date of Electronic Publication: 2018 Nov 27.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Camptothecin/*analogs & derivatives
Carcinoembryonic Antigen/*blood
Cetuximab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Cetuximab/adverse effects ; Clinical Trials, Phase III as Topic ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Male ; Middle Aged ; Multicenter Studies as Topic ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Risk Factors ; Time Factors ; Up-Regulation
SCR Protocol :
IFL protocol
Czasopismo naukowe
Tytuł :
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Autorzy :
Modest DP; Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address: .
Ricard I; Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany.
Stintzing S; Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Fischer von Weikersthal L; Gesundheitszentrum St. Marien, Amberg, Germany.
Decker T; Oncological Practice, Ravensburg, Germany.
Kiani A; Medizinische Klinik IV, Klinikum Bayreuth, Bayreuth, Germany.
Vehling-Kaiser U; Oncological Practice, Landshut, Germany.
Al-Batran SE; Department of Hematology and Oncology, Krankenhaus Nordwest Frankfurt/Main, Germany.
Heintges T; Department of Medicine II, Städtisches Klinikum Neuss, Germany.
Kahl C; Haematology and Oncology, Staedtisches Klinikum Magdeburg, Germany.
Seipelt G; Oncological Practice, Bad Soden, Germany.
Kullmann F; Department of Medicine I, Klinikum Weiden, Germany.
Scheithauer W; Department of Internal Medicine I and Comprehensive Cancer Center, Medical University Vienna, Austria.
Moehler M; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany; Medical Department 1, Johannes-Gutenberg Universität Mainz, Mainz, Germany; University Cancer Center Frankfurt/Mainz, Germany.
Westphalen CB; Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Germany.
Holch JW; Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Germany.
von Einem JC; Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Germany.
Held S; ClinAssess GmbH, Leverkusen, Germany.
Heinemann V; Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Pokaż więcej
Corporate Authors :
for FIRE-3/AIOKRK0306-investigators
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Oct; Vol. 84, pp. 262-269. Date of Electronic Publication: 2017 Aug 23.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bevacizumab/*therapeutic use
Camptothecin/*analogs & derivatives
Cetuximab/*therapeutic use
Colorectal Neoplasms/*drug therapy
Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Biomarkers, Tumor/genetics ; Camptothecin/adverse effects ; Camptothecin/therapeutic use ; Cetuximab/adverse effects ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Humans ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Leucovorin/adverse effects ; Leucovorin/therapeutic use ; Mutation ; Neoplasm Metastasis ; Proportional Hazards Models ; Proto-Oncogene Proteins p21(ras)/genetics ; Risk Factors ; Time Factors ; Treatment Outcome
SCR Protocol :
IFL protocol
Czasopismo naukowe
Tytuł :
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Autorzy :
Modest DP; Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Stintzing S; Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Fischer von Weikersthal L; Gesundheitszentrum St. Marien, Amberg, Germany.
Decker T; Oncological Practice, Ravensburg, Germany.
Kiani A; Klinikum Bayreuth, Medizinische Klinik IV, Bayreuth, Germany.
Vehling-Kaiser U; Oncological Practice, Landshut, Germany.
Al-Batran SE; Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt/Main, Germany.
Heintges T; Department of Medicine II, Städtisches Klinikum Neuss, Neuss, Germany.
Lerchenmüller C; Oncological Practice, Münster, Germany.
Kahl C; Haematology and Oncology, Staedtisches Klinikum Magdeburg, Magdeburg, Germany.
Seipelt G; Oncological Practice, Bad Soden, Germany.
Kullmann F; Department of Medicine I, Klinikum Weiden, Weiden in der Oberpfalz, Germany.
Scheithauer W; Department of Internal Medicine I & Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
Kirchner T; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Institute of Pathology University of Munich, Munich, Germany.
Jung A; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Institute of Pathology University of Munich, Munich, Germany.
Stauch M; Oncological Practice, Kronach, Germany.
von Einem JC; Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany.
Moehler M; Medical Department 1, Johannes-Gutenberg Universität Mainz, Mainz; University Cancer Center Frankfurt/Mainz, Frankfurt/Mainz, Germany.
Held S; ClinAssess GmbH, Leverkusen, Germany.
Heinemann V; Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.
Pokaż więcej
Corporate Authors :
FIRE-3 study investigators
Źródło :
International journal of cancer [Int J Cancer] 2017 Apr 15; Vol. 140 (8), pp. 1918-1925. Date of Electronic Publication: 2017 Feb 08.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Camptothecin/*analogs & derivatives
Cetuximab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Adult ; Aged ; Camptothecin/administration & dosage ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Disease-Free Survival ; Female ; Fluorouracil/administration & dosage ; Humans ; Kaplan-Meier Estimate ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Proto-Oncogene Proteins p21(ras)/genetics ; Remission Induction ; Treatment Outcome
SCR Protocol :
IFL protocol
Czasopismo naukowe
Tytuł :
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Autorzy :
Michl M; Department of Hematology and Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center Munich, Ludwig-Maximilians-University Munich, Munich .
Stintzing S; Department of Hematology and Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center Munich, Ludwig-Maximilians-University Munich, Munich German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg.
Fischer von Weikersthal L; Practice for Hematology and Medical Oncology, Gesundheitszentrum St Marien, Amberg.
Decker T; Practice for Hematology and Medical Oncology, Onkonet-Onkologie Ravensburg, Ravensburg.
Kiani A; Department of Hematology and Medical Oncology, Klinik Herzoghöhe, Bayreuth.
Vehling-Kaiser U; Practice for Hematology and Medical Oncology, Landshut.
Al-Batran SE; Department of Hematology and Medical Oncology, Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt.
Heintges T; Department of Gastroenterology and Oncology, Medical Department II, Lukaskrankenhaus, Städtisches Klinikum Neuss, Neuss.
Lerchenmueller C; Practice for Hematology and Medical Oncology, Muenster.
Kahl C; Department of Hematology and Medical Oncology, Klinikum Magdeburg, Magdeburg.
Seipelt G; Practice for Hematology and Medical Oncology, Bad Soden.
Kullmann F; Department of Gastroenterology, Hematology and Medical Oncology, Klinikum Weiden, Weiden.
Stauch M; Practice for Hematology and Medical Oncology, Kronach, Germany.
Scheithauer W; Department of Hematology and Medical Oncology, Medical University of Vienna, Vienna, Austria.
Hielscher J; Department of Surgery, Klinikum Chemnitz, Chemnitz.
Scholz M; Department of Medicine, Klinikum Stuttgart, Stuttgart.
Mueller S; Practice for Hematology and Medical Oncology, Ansbach.
Lerch MM; Department of Medicine A, University Medicine Greifswald, Greifswald.
Modest DP; Department of Hematology and Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center Munich, Ludwig-Maximilians-University Munich, Munich German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg.
Kirchner T; Department of Pathology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg.
Jung A; Department of Pathology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg.
Heinemann V; Department of Hematology and Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center Munich, Ludwig-Maximilians-University Munich, Munich German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg.
Pokaż więcej
Corporate Authors :
FIRE-3 Study Group
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Aug; Vol. 27 (8), pp. 1565-72. Date of Electronic Publication: 2016 May 27.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Camptothecin/*analogs & derivatives
Carcinoembryonic Antigen/*genetics
Cetuximab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Proto-Oncogene Proteins p21(ras)/*genetics
Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Cetuximab/adverse effects ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Disease-Free Survival ; Exons/genetics ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Kaplan-Meier Estimate ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Male ; Middle Aged ; Mutation
SCR Protocol :
IFL protocol
Czasopismo naukowe
    Wyświetlanie 1-11 z 11

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies